经观健康 2025年1-8月，中国创新药BD（狭义：药物对外授权）交易首付款超300亿元，已超同期一级市场融资 额，在二级市场，BD推动了创新药行业进入第二个市值高峰。 BD，无疑是今年创新药行业乃至中国股市的关键词之一。 近期，美国相关行政命令草案、个别出海药物临床数据争议，又让市场对BD热潮陷入迷茫和犹疑。 经济观察报【分子圆桌派第一期：重估BD】由经济观察报大健康新闻部主任张英主持，中国生物制药 执行董事、资深副总裁谢炘、中信证券医疗健康产业首席分析师陈竹就2025年中国创新药行业的BD热 潮展开了探讨，以下为此次主题沙龙的相关实录。 张英：大家好，欢迎来到经济观察报《分子圆桌派》，我是今天的主持人张英。今年以来，创新药BD 交易吹动了股市热，也推动了多家创新药企进入第二个市值高峰。不过我们也关注到近期多家创新药企 的股价有一定的回调，那么近期美国的相关行政命令草案以及个别出海药物的临床数据争议，也让部分 市场人士对当前的创新药 BD 热潮陷入了这个迷茫和犹疑。在此背景之下，分子圆桌派第一期我们将聚 焦今年的创新药 BD 热潮，重估它的价值和前景。 张英：以及中信证券医疗健康产业首席分析师陈竹，陈老师。 ...

Core Insights - The innovative drug industry in 2025 is witnessing a surge in business development (BD) activities, with over 70 pipeline licensing agreements signed by Chinese pharmaceutical companies in the first half of the year, totaling over $60 billion, setting a historical record [1] - The urgency of multinational pharmaceutical companies to fill the "patent cliff" gap has positioned Chinese firms as significant sources of global pipelines due to their efficient R&D and cost advantages [1] Company Overview - Baiaosaitu's growth path can be summarized as "from point to surface," starting with gene-edited mice and accumulating industry-leading humanized mouse resources, providing stable cash flow and early engagement with innovative drug companies [2] - The company's antibody discovery platform, initiated in 2020 with the "Thousand Mice, Ten Thousand Antibodies" plan, has positioned Baiaosaitu at the forefront of the innovative drug R&D chain, enabling partners to significantly reduce time and uncertainty in the development process [2] - Baiaosaitu operates a "dual business line" model: stable cash flow from standardized model animal products and high-growth potential from high-throughput antibody production through licensing and collaboration [2] Market Valuation Logic - In the secondary market, traditional biotech companies often rely on a few pipeline "stories" for high valuations, which carry significant risks and volatility, while Baiaosaitu's platform-centric model offers stronger risk resilience [3] - The value of platform-based biotech lies in its ability to "empower" others, sharing clinical risks and revenues through collaborations and licensing, functioning as a "R&D infrastructure" for global innovative drug companies [3] Recent Collaborations - In September, Baiaosaitu announced three international collaborations, further demonstrating the value of its platform [4] - The collaboration with Merck explores antibody-conjugated LNP nucleic acid delivery, expanding the boundaries of antibody applications in emerging therapies and creating potential long-term cash flow [5] - A licensing agreement with Tubulis involves a fully human antibody derived from the RenMice® platform entering ADC development, exemplifying the "antibody supermarket" model by allowing molecules to enter clinical trials through licensing rather than self-research [6] - The partnership with IDEAYA focuses on the dual-antibody ADC IDE034, with preclinical data showing significant synergy when combined with small molecule drugs, highlighting Baiaosaitu's technical capabilities in this hot sector [7] Role in Business Development Wave - Multinational pharmaceutical companies are willing to pay high prices for early pipeline access, and Chinese firms are achieving a positive cycle of funding and technology through BD, with Baiaosaitu's model aligning well with this trend [9] - The open platform allows molecules to be licensed multiple times to different partners, increasing the probability of success, while the value capture model includes upfront payments, milestones, and sales shares, forming a long-term "value pyramid" [9] - Baiaosaitu serves as an "accelerator" for new drug development, providing "ready-to-use" candidate molecules for various-sized pharmaceutical companies, thus lowering innovation barriers [9] - The company's story reflects the rise of Chinese biotech and the inevitable result of the fine division of labor in the innovative drug industry, with BD transactions expected to be a long-term trend driven by the "patent cliff" and "efficiency dividend" [9]

Core Viewpoint - The collaboration between Maiwei Biotech and Calico is noteworthy as it marks a significant shift in the innovation drug landscape, leading to a substantial increase in Maiwei's stock price and market capitalization [2][3]. Company Overview - Maiwei Biotech, established 8 years ago, has gained prominence in the innovative drug sector, with its stock price increasing over 140% this year, reaching a market cap close to 240 billion yuan [2]. - The company has a focus on First-in-Class products, emphasizing deep understanding of biological mechanisms and disease relationships as the foundation for innovation [2][8]. Business Development (BD) Strategy - The partnership with Calico, a leader in anti-aging research, was formed after a swift negotiation process of just five months, highlighting the efficiency of the BD project [3]. - Maiwei's previous BD project involved a collaboration with DISC for a monoclonal antibody targeting TMPRSS6, also a First-in-Class product, indicating a trend of proactive interest from potential partners [4]. Clinical Development and Product Pipeline - Maiwei Biotech has multiple ADCs (Antibody-Drug Conjugates) in clinical trials, with 2025 designated as a key year for BD activities, further fueling market enthusiasm [5]. - The company has maintained a steady pace of product approvals since its listing on the STAR Market in 2022, with significant sales growth reported for its biosimilar products [6]. Market Position and Future Outlook - The company aims to build a comprehensive innovation ecosystem, focusing on First-in-Class and Best-in-Class products, while also exploring unique ADC development strategies [7][9]. - Maiwei's approach to BD emphasizes the importance of understanding target mechanisms and disease relationships, setting it apart from many biotech firms that focus solely on technical iterations [8]. Innovative Sales Strategies - The company is considering a "shared sales" model to enhance efficiency and reduce costs by collaborating with other biotech firms to form a unified sales team [11]. - This strategy reflects a flexible approach to navigating the competitive landscape of the Chinese pharmaceutical market, which is characterized by intense competition and a predominance of generic drugs [10].

9月11日，海外利空突袭，AH创新药最终扛住了！ 盘初恐慌情绪集中释放，AH创新药全线重挫，重仓A股创新药的药ETF（562050）一度跌逾4%，100% 聚焦创新药的港股通创新药ETF（520880）跌幅接近8%。 情绪大肆发泄后，行情逐渐缓和，午后明显企稳，药ETF（562050）场内微跌0.7%报收，港股通创新药 ETF（520880）场内最终收跌1.82%，全天振幅达6.67%，成交9.28亿元，环比激增逾88%。 | 序号 | 代码 | 名称 | 现价 | 涨跌幅 | 总市值 | 估算权重 | | --- | --- | --- | --- | --- | --- | --- | | 1 | 9926 | 康方生物 | 127.700 | -4.34% | 1176亿 | 8.54% | | 2 | 1801 | 信达生物 | 97.100 | -2.51% | 1663亿 | 9.43% | | 3 | 1093 | 石药集团 | 10.120 | -7.50% | 1166亿 | 10.14% | | 4 | 6160 | 白济神州 | 193.800 | -6.92% | 2934Z | 10 ...

9月11日，港股创新药剧烈调整，翰森制药、石药集团、百济神州、中国生物制药、康方生物等千亿市 值龙头齐挫，多股跌超6%。 创新药纯度100%的港股通创新药ETF（520880）跳空低开后一度跌逾7%，午后低位震荡，尾盘发力回 升，场内收跌1．82%，全天成交超9．28亿元，环比激增超88%。 什么原因？消息面上，据外媒报道，特朗普政府可能草拟法案，对中国药品实施严厉的限制和审查措 施。市场担心中国创新药BD被打断，行情波动加大。 如何看待？港股通创新药ETF（520880）基金经理丰晨成火线解读： 1、矛头为何对准中国创新药BD？ 结合公开信息，该法案当前尚在起草阶段，白宫明确表示"不在优先事项"。事件本质是美国生物医药产 业在早期研发和效率上开始落后中国，美国生物医药指数今年以来大幅跑输中国生物医药指数，引发美 国早期投资人的不满和保守派人士的担忧。 2、传言会否成真？ 美国禁止中国创新药BD基本不可实现。 首先，这直接挑战川普阵营的基本盘和支持者，以及美国大药企MNC的根本利益。美国制药业龙头辉 瑞就明确表示，限制中国创新药将使得MNC错失获得最好的研发分子并进一步落后研发进度； 其次，如果失去中国的快速 ...

Group 1 - The A-share innovative drug sector experienced a strong rebound, with the Biopharmaceutical ETF (159839) rising by 4.17% and a trading volume exceeding 44 million yuan [1] - The Biopharmaceutical ETF (159839) has seen a net inflow of over 15 million yuan for two consecutive days [1] - Several innovative drug companies reported significant stock price increases, with notable gains including 9.99% for Zhaoyan New Drug and 7.53% for Changchun High-tech [2] Group 2 - The pharmaceutical industry is experiencing structural differentiation, with a 0.7% decline in revenue and a 1.5% increase in net profit for listed companies in the first half of 2025 [3] - Leading innovative drug companies are achieving profitability, driven by strong sales of key products such as Zebutinib and Furmetinib [3] - The innovative drug sector is expected to benefit from improved policies and a downward trend in global central bank interest rates, which may enhance long-term valuations [4] Group 3 - The CXO industry is entering a recovery phase, with a resurgence in overseas demand expected by the end of 2023, leading to a recovery in domestic head companies' orders in 2024 [5] - The domestic innovative drug assets are progressing into late clinical stages, with increasing validation of clinical data and a clear trend towards internationalization [5]

Core Viewpoint - BeiGene has entered into an agreement with Royalty Pharma to sell the rights to receive royalties from the global sales of tarlatamab outside of China, with a maximum transaction value of $950 million [1] Group 1: Transaction Details - BeiGene will receive an upfront payment of $885 million and has the option to sell the remaining royalty rights within 12 months for an additional $65 million [1] - The company will also earn a share of revenues from annual sales exceeding $1.5 billion [1] - The transaction does not involve the transfer of any intellectual property rights, indicating a new path for business development in innovative drug companies [1][2] Group 2: Industry Context - The financing tools for innovative drug companies in China are becoming increasingly diversified, moving beyond traditional equity financing and business development transactions [2] - The DLL3 target is experiencing intense competition in drug development and commercialization, with tarlatamab being the first approved DLL3-targeted drug globally [2][7] - The collaboration with Royalty Pharma represents a shift towards royalty transactions in the Chinese innovative drug market, which has been dominated by traditional licensing models [3][5] Group 3: Royalty Pharma's Role - Royalty Pharma is a leading player in the royalty transaction market, having deployed over $25 billion in capital and completed over 80 royalty acquisitions, holding more than 60% market share [3][4] - The company has previously engaged in significant royalty transactions for well-known drugs, indicating its strong position in the market [4] Group 4: Future Prospects - Tarlatamab is expected to provide new treatment options for small cell lung cancer (SCLC) patients in China, with ongoing clinical studies showing positive results [6] - The innovative drug market is seeing a surge in activity, with numerous significant business development transactions enhancing the interest in DLL3-targeted therapies [8] - BeiGene's recent financial performance indicates a turnaround, with a reported operating profit of 799 million yuan and a net profit of 450 million yuan, marking a return to profitability [9]

Group 1 - Business Development (BD) is a significant trend in the domestic medical device industry, with a notable increase in BD transactions for innovative drugs, reaching a total of $60.8 billion in the first half of the year, surpassing the total for 2024 [1] - The Chinese government is promoting the development of domestic medical devices, with a focus on high-end medical equipment and technologies such as medical robots and AI medical devices, as outlined in the announcement released in July 2025 [2] - There is a fundamental difference in the evaluation systems and investment models between innovative drugs and medical devices, with medical devices requiring more extensive market and academic investment for recognition in different markets [3] Group 2 - The current BD model for medical devices is not suitable for a simple license-out approach due to the high dependency on usage scenarios and the experience of practitioners, which complicates the management and control of subsequent clinical trials and registrations [4] - Although the current BD model for innovative drugs may not fit medical devices, there are still BD transactions occurring in the medical device sector, such as the joint venture established between China Medical Device Co., Ltd. and GE Healthcare China [5] - The recently published "Medical Device BD White Paper 2025" indicates that BD in the medical device sector encompasses various transaction activities, including technology licensing, joint development, and strategic investments, with a focus on the actual product deployment [6] Group 3 - The trend in medical device BD is shifting from single transactions to a more structured resource allocation system, with an increasing willingness among investors and partners to engage in the early stages of product development and registration [7]

Market Overview - The market showed mixed performance with the Shanghai Composite Index reaching a new high for the year, while the Shenzhen Component and ChiNext Index experienced slight declines [1][11] - The total trading volume in the Shanghai and Shenzhen markets was 1.09 trillion yuan, a decrease of 43.2 billion yuan compared to the previous trading day [1] Sector Performance - The pharmaceutical sector remained active, with multiple stocks such as Chenxin Pharmaceutical and others hitting the daily limit [1][3] - The film and entertainment sector saw a resurgence, particularly with the film "Nanjing Photo Studio" performing well, grossing over 600 million yuan within five days of its release [3][14] - The steel sector also showed strength, with Xining Special Steel achieving seven consecutive trading limits [5][27] Individual Stock Highlights - A total of 32 stocks hit the daily limit, with a sealing rate of 69%, and nine stocks achieved consecutive limits [1][13] - Notable performers included Chenxin Pharmaceutical with five consecutive limits and Xizang Tourism with eight consecutive limits [1][21] Investment Opportunities - The ongoing trend in innovative pharmaceuticals is highlighted by the collaboration between Heng Rui Pharmaceutical and GlaxoSmithKline, potentially worth up to 12.5 billion USD [5] - The film industry is expected to see steady growth due to the successful release of quality films during the summer season [3][14] Regulatory and Policy Insights - The China Steel Industry Association emphasized the need for self-discipline and stable pricing in the steel industry amid ongoing capacity governance policies [9] - The National Development and Reform Commission is seeking public input on guidelines for government investment funds, aiming to enhance long-term capital deployment [34]

Group 1: Company Developments - The stock of "Giant Star Legend," associated with Jay Chou, surged nearly 30% after announcing a partnership with Yushutech for the development of consumer-grade robots [3][11][13] - The collaboration will focus on creating robots with strong IP attributes, leveraging both companies' strengths in marketing and technology [13] - Giant Star Legend's business is divided into two main segments: IP creation and operation, and new consumption, with a strong connection to celebrity endorsements [13] Group 2: Market Trends - The A-share market saw a collective decline in major indices, while the Shanghai Composite Index briefly turned positive [1] - Coal and oil & gas stocks were active, while sectors like film and military electronics showed slight gains [3] - The innovation drug sector remained active, with companies like Chenxin Pharmaceutical experiencing significant stock increases [7][9] Group 3: Regulatory and Industry Insights - The State Post Bureau held a meeting to address issues in the express delivery industry, focusing on regulatory compliance and high-quality development [6] - The innovation drug sector is witnessing a surge in business development (BD) deals, with a notable partnership between Heng Rui Pharmaceutical and GlaxoSmithKline potentially worth up to $12.5 billion [9]